Pharma BD Deal Intelligence

Gilead Sciences, Inc. (via Kite) / Interius BioTherapeutics, Inc.

2025 · Acquisition/Merger · $350M · Complete

Announcement Sentiment

Strongly positive

Gilead's Kite subsidiary agreed to acquire Interius BioTherapeutics for $350M, gaining in vivo CAR-T platform technology and INT2104, one of the first in vivo cell therapies in human trials. Integrates into Kite's Philadelphia research team.

Key facts

Announced Aug 20, 2025
Deal value $350M
Deal type Acquisition/Merger
Therapeutic area Hematologic malignancies (initial)
Indications Hematologic malignancies (initial)
Key assets INT2104
Mechanism In vivo CAR-T via integrating lentiviral delivery

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals